Added to YB: 2026-02-10
Pitch date: 2026-02-06
KOD [neutral]
Kodiak Sciences Inc.
+63.79%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Market Cap
$2.5B
Pitch Price
$22.84
Price Target
N/A
Dividend
N/A
EV/EBITDA
-10.95
P/E
-9.53
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Biotech Catalysts on My Radar | February 2026 - Kodiak Sciences Inc.
KOD (quick overview): Phase 1b APEX data readout Feb 7, 2026 for bispecific retinal therapy in diabetic macular edema & inflammation-related macular edema. Early test of biological activity after prior setbacks. Positive: retinal fluid reduction, visual improvement, acceptable safety. Negative: platform translation doubts persist.
Read full article (2 min)